The future of human gene therapy

Molecular Aspects of Medicine

Volumn 22, Issue 3, 2001, Pages 113-142

  Rubanyi, Gabor M ^a  

^a BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ENDOTHELIAL CELL GROWTH FACTOR; FAS LIGAND; GROWTH FACTOR; MESSENGER RNA; NITRIC OXIDE SYNTHASE; PLASMID DNA; VASCULOTROPIN; VIRUS VECTOR;

ADENOVIRUS; ANGIOGENESIS; BIOENGINEERING; CANCER THERAPY; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DNA VECTOR; GENE EXPRESSION; GENE TARGETING; GENE TECHNOLOGY; GENE THERAPY; GENE TRANSFER; HUMAN; MOLECULAR CLONING; MOLECULAR GENETICS; NONHUMAN; SAFETY;

ANIMALS; FORECASTING; GENE THERAPY; HUMANS;

EID: 0034915984     PISSN: 00982997     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0098-2997(01)00004-8     Document Type: Conference Paper

References (142)

1. Lentiviral vectors: The promise of gene therapy within reach?
2. Human gene therapy
3. The delivery of angiogenic factors to the heart by microsphere therapy
4. Stem cell therapy and gene transfer for regeneration
5. Inhibition of intimal hyperplasia after vein grafting by in vivo transfer of human senescent cell-derived inhibitor-1 gene
6. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs
7. Dendritic cells and the control of immunity
8. 165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia
9. Isolation of a common receptor for coxsacki B viruses and adenoviruses 2 and 5
10. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
11. Myocardial gene transfer by selective pressure regulated retroinfusion of coronary veins
12. Adenoviral-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer
13. Reports of adenovector 'death' are greatly exaggerated
14. Gene therapy as drug development
15. Immune events associated with the cure if established tumors and spontaneous metastases by local and systemic interleukin 12
16. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
17. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty
18. Cyctostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product
19. Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products
20. Controlling mammalian gene expression with small molecules
21. Regulated gene expression systems
22. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk
23. Mouse model of angiogenesis
24. Gene therapy for restenosis: Are we ready?
25. Targeted gene delivery by tropism-modified adenoviral vectors
26. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte macrophage colony stimulating factor stimulates potent, specific, and long lasting anti-tumor immunity
27. Progress and potential for gene-based medicine
28. Gene therapy for vascular disease
29. Clinical applications of research on angiogenesis
30. Bystander effect in the adenovirus-mediated wild-type p53 gene therapy model of human squamous cell carcinoma of the head and neck
31. Cell therapy
32. Molecular therapies for vascular diseases
33. Intracoronary gene-transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart
34. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters
35. Inhibition of vascular smooth muscle cell proliferation and neointimal accumulation by adenovirus-mediated gene transfer of cytosine deaminase
36. Frequency and stability of chromosomal integration of adenovirus vectors
37. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
38. Double blind, placebo controlled trial of recombinant human vascular endothelial growth factor: The VIVA Trial
39. Dimeric ligands define a role for transcriptional activation domains in reinitiation
40. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
41. Researchers and regulators reflect in first gene therapy death
42. Role of bone marrow derived cells in presenting MHC class I-restricted tumor antigens
43. Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo
44. Angiogenesis and collateral formation
45. 165 in patient with ischamic limb
46. Development of a novel fusogenic viral liposome system (HVJ-liposomes) and its applications to the treatment of acquired diseases
47. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
48. Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models
49. Genetic targeting of adenoviral vectors
50. Intracoronary administration of recombinant fibroblast growth factor (rFGF-2) in patients with severe coronary artery disease: Results of phase I
51. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: Results of a phase I randomized, double-blind, placebo-controlled trial
52. Results of Phase I open label dose escalation study of intracoronary and intravenous FGF-2 in patients with severe ischemic heart disease: 6 months follows-up
53. Catheter-mediated VEGF gene transfer to human coronary arteries after angioplasty
54. Ultrasound enhances reporter gene expression after transfection of vascular cells in vitro
55. Reversed-phase high-performance liquid chromatographic assay for the adenovirus type 5 proteome
56. Virus treatment questioned after gene therapy death
57. Nonviral gene therapy: Promises and challenges
58. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice
59. Systemic gene delivery expands the repertoire of effective antiangiogenic agents
60. Gene Therapy for myocardial angiogenesis: Initial clinical results with direct myocardial injection of phVEGF as sole therapy for myocardial ischaemia
61. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart
62. Pharmacologic control of humanized gene therapy system implanted into nude mice
63. Catheter-mediated VEGF gene transfer to human lower limb arteries after PTA
64. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: The PREVENT single-centre, randomized, controlled trial
65. Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: Overexpression of caspase-7 as a new gene therapy strategy for prostate cancer
66. Gene therapy for cancer: Managing expectations
67. High-efficiency gene transfer into skeletal muscle mediated by electric pulses
68. AAV vectors: Is clinical success on the horizon?
69. Drug sensitivity (`suicide') genes for selective cancer chemotherapy
70. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia
71. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo
72. kB binding site prevents myocardial infarction
73. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice
74. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia
75. Complex models for the study of gene function in cardiovascular biology
76. Role of αν integrins in adenovirus cell entry and gene delivery
77. Vascular endothelial growth factor (VEGF) and its receptors
78. Adenovirus-mediated gene transfer into normal arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia
79. Ecdysone-inducible gene expression in mammalian cells and transgenic mice
80. Gene therapy for vascular smooth muscle cell proliferation after arterial injury
81. Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: A pilot study in humans
82. Indentification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen
83. Specific tumor-cell killing with adenovirus vectors containing the apoptin gene
84. Activation of the complement system by synthetic DNA complexes: A potential barrier for intravenous gene delivery
85. Immunotherapy of malignancy by in vivo gene transfer into tumors
86. Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease
87. A humanized system for pharmacologic control of gene expression
88. Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease
89. Replicating vectors for cancer therapy: A question of strategy
90. Gene therapy for restenosis: Getting nearer the heart of the matter
91. Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response
92. Induction of neoangiogenesis in ischemic myocardium by human growth factors: First clinical results of a new treatment of coronary heart disease
93. Therapeutic angiogenesis with basic fibroblast growth factor: Technique and early results
94. Development of a hypoxia-responsive vector for tumor-specific gene therapy
95. Highly augmented cytopathic effort of a fibermutant E1B-defective adenovirus of gene therapy of gliomas
96. Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimbs
97. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo
98. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastic melanoma
99. VEGF gene delivery to muscle: potential role for vasculogenesis in adults
100. A new cationic liposome DNA complex enhances the efficiency of arterial gene transfer in vivo
101. Hematopoietic stem-cell based gene therapy for acquired immuno-deficiency syndrome: Efficient transduction and expression of RevM10 in myeloid cells in vivo and in vitro
102. Efficient and stable transduction of cardiomyocytes after intramocardial injection or intracoronary perfusion with recombinant adeno-associated virus vector
103. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease
104. Ischemia and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization
105. Therapeutic angiogenesis: A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model
106. Targeting angiogenesis: Genetic intervention which strikes at the weak link of tumorigenesis
107. Expression of cyclin-dependent kinase inhibitors in vascular disease
108. NOS inhibition reduced angiogenic factor-induced collateral blood flow expansion
109. Glucose regulated production of human insulin in rat hepatocytes
110. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors
111. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion
112. Efficient adventitial gene delivery to rabbit carotid artery with cationic polymer-plasmid complexes
113. Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium
114. Physiologically responsive gene therapy
115. Gene therapy promises, problems and prospects
116. Strategies for achieving multiple layers of selectivity in gene therapy
117. Microbubbles targeted to intercellular adhesion molecule-1 bind to activated coronary artery endothelial cells
118. Gene therapy inhibiting neointimal vascular lesion: In vivo transfer of endothelial cell nitric oxide synthase gene
119. A regulatory system for use in gene trasfer
120. The human genome project: Past, present and future
121. Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase
122. Targeting adenovirus
123. Integrins ανβ3 and ανβ5 promote adenovirus internalization but not virus attachment
124. Adenovirus targeted to heparin-containing receptors increases its gene delivery efficiency to multiple cell types
125. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins
126. Adenoviruses as gene delivery vehicles
127. Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumor tissue
128. Effects of epidermal growth factor, transferrin, and insulin on lipofection efficiency in human lung carcinoma cells
129. Gene gun and other non-viral approaches for cancer gene therapy
130. Angiotensin-converting enzyme inhibition increases collateral dependent muscle blood flow
131. Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury
132. A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes
133. Vascular gene transfer
134. Cardiovascular gene therapy
135. Transfer of wild-type p53 gene effectively inhibits vascular smooth muscle cell proliferation in vitro and in vivo
136. Roles of adeno-associated virus Rep protein and human chromosome 19 in site-specific recombination